

Regence

Medical Policy Manual

Medicine, Policy No. 40

Prolotherapy

Effective: May 1, 2024

Next Review: January 2025

Last Review: March 2024

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Prolotherapy describes a procedure intended for healing and strengthening ligaments and tendons by injecting an agent that induces inflammation and stimulates endogenous repair mechanisms. Prolotherapy may also be referred to as proliferant injection, prolo, joint sclerotherapy, regenerative injection therapy, growth factor stimulation injection, or nonsurgical tendon, ligament, and joint reconstruction.

MEDICAL POLICY CRITERIA

Prolotherapy is considered **investigational** as a treatment of any condition, including but not limited to musculoskeletal pain.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

CROSS REFERENCES

None

BACKGROUND

Prolotherapy has been investigated as a treatment of various etiologies of pain, including

arthritis, degenerative disc disease, fibromyalgia, tendinitis, and plantar fasciitis. As with any therapy for pain, a placebo effect could be anticipated. Therefore, data from adequately powered, blinded, randomized placebo-controlled trials (RCTs) are required to control for the placebo effect in order to determine whether any treatment effect from prolotherapy exceeds that over placebo. The focus of the following evidence review is on systematic reviews (SRs) and RCTs.

EVIDENCE SUMMARY

CHRONIC BACK AND NECK PAIN

Systematic Reviews

An updated 2007 Cochrane SR on prolotherapy for chronic low-back pain concluded that “when used alone, prolotherapy is not an effective treatment for chronic low-back pain.”^[1] The authors also concluded that, although confounded by co-interventions and the heterogeneity of studies, “when combined with spinal manipulation, exercise, and other interventions, prolotherapy may improve chronic low-back pain and disability.”^[2]

The similar evidence was evaluated in a 2008 and 2009 SR, one of which was conducted for the American Pain Society.^[3] The authors of this review concluded that prolotherapy was found to be ineffective when used alone for chronic low back pain.

Randomized Controlled Trials

Kim (2010) compared intra-articular prolotherapy with intra-articular corticosteroid injection for sacroiliac (SI) joint pain.^[4] The randomized double-blinded study included 48 patients with SI joint pain of at least three months duration, confirmed by 50% or greater improvement in response to SI joint local anesthetic block. A maximum of three injections were performed on a biweekly schedule under fluoroscopic guidance with confirmation of the intra-articular location with an arthrogram. Pain and disability scores were assessed at baseline, two weeks, and monthly after completion of treatment. At two weeks after treatment, all patients met the primary outcome measure of at least 50% reduction in pain scores, and there was no significant difference between the two groups. The numerical rating scale for pain was reduced from 6.3 to 1.4 in the prolotherapy group and from 6.7 to 1.9 in the steroid group. The Oswestry Disability Index (ODI) decreased from 33.9 to 11.1 in the prolotherapy group and from 35.7 to 15.5 in the steroid group. Kaplan-Meier survival analysis showed a significantly greater percentage of patients with sustained relief following prolotherapy. At six months and 15 months after treatment, 63.6% and 58.7%, respectively, of patients in the prolotherapy group reported at least 50% improvement from baseline in comparison with 27.2% and 10.2%, respectively, of the steroid group. Key differences between this and other studies on prolotherapy were the selection of patients using a diagnostic sacroiliac joint block and the use of an arthrogram to confirm the location of the injection. Additional trials are needed to confirm the safety and efficacy of this procedure.

OSTEOARTHRITIS

Systematic Reviews

Cortez (2022) conducted a systematic review involving eight RCTs (N=660) that compared dextrose prolotherapy with other substances for pain relief (e.g., platelet-rich plasma, exercise programs, hyaluronic acid, saline) in patients with primary knee osteoarthritis.^[5] Study size

ranged from 42 to 120 patients with gender distribution leaning heavily toward the female sex (61% of the total population). Study assessments ranged from 0 to 52 weeks with the majority of study investigators performing assessments at months 1, 3, and 6. Only 2 studies continued assessments up to the 52 week mark. Dextrose intra-articular injections were primarily applied at weekly or monthly intervals and most studies performed a total of 3 injections. Concentrations of dextrose injections ranged from 12.5% to 25% with 10 mL as the most prevalent volume injected. Overall, patients who underwent dextrose prolotherapy had numerical improvements between baseline and posterior assessments when compared to saline injections regarding pain and function with between-group differences of 7.73 to 14 points on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale and 1.06 to 3.5 points on visual analogue scale (VAS). However, the results were unclear when comparing dextrose prolotherapy to other substances. The included studies were limited by small sample sizes and the limited time frame for patient assessment. Due to significant heterogeneity of the studies, the intended meta-analysis could not be performed and no conclusions can be drawn based on these findings.

Arias-Vazquez (2022) completed a systematic review and meta-analysis involving six studies (five clinical trials and an observational study) of 395 patients with knee osteoarthritis comparing the effectiveness of hypertonic dextrose prolotherapy with intra-articular hyaluronic acid injections on pain reduction and improvement of function.^[6] The primary outcomes were pain control (as measured by VAS or the pain subscale score of validated questionnaires) and improvement in function (as measured by scores on validated questionnaires). Both outcomes were assessed at three months follow-up. Two hundred patients were treated with hypertonic dextrose prolotherapy and 195 were administered intra-articular hyaluronic acid injections. The groups who received hypertonic dextrose prolotherapy used a solution of hypertonic dextrose combined with local anesthetics, with up to three intra-articular injections dependent on study design. For those who received hyaluronic acid, up to five intra-articular injections were administered dependent on study design. Pooled results of the clinical trials revealed no significant difference in pain reduction between hypertonic dextrose prolotherapy and hyaluronic acid in the short-term (three months; $p=.06$); however, a significant difference in improvement of function was observed in favor of the hypertonic dextrose prolotherapy group ($p=0.03$). No major adverse effects were reported in the three studies reporting adverse reactions. Limitations included the small total number of studies, short-term follow-up, unclear or high risk of study bias, and significant data heterogeneity. Better quality clinical trials are necessary to corroborate these results.

Wee (2021) published a systematic review and meta-analysis involving 11 RCTs (N=837) that evaluated the use of dextrose prolotherapy in knee osteoarthritis.^[7] The included studies compared dextrose prolotherapy to other injectates (active or placebo) or interventions in adults with a knee osteoarthritis diagnosis and included three of the RCTs of prolotherapy in knee osteoarthritis summarized below. The conclusion from the review and analysis identified prolotherapy in knee osteoarthritis to be of potential benefit for pain but the studies are at high risk of bias. Only two of the well-designed studies could be used as an unbiased potential consideration of dextrose prolotherapy in knee osteoarthritis. In general, the review identified that the treatment is safe and may be considered only in patients with limited alternative options.

Additional systematic reviews have been conducted which include similar trials as the reviews described above and have similar limitations that limit their interpretation and conclusions due to high risk of bias and heterogeneity.^[8]

Randomized Controlled Trials

Sert (2020) reported on an RCT of prolotherapy in symptomatic knee osteoarthritis refractory to conservative therapy.^[9] A total of 66 patients between the ages of 40 to 70 years were randomized to dextrose prolotherapy, saline injection, or a control group. Injections were blinded and given at zero, three, and six weeks, while the control group was not blinded. All groups performed an at home exercise program. At 18 weeks, the primary outcome, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score was significantly improved in all groups, with the change in the prolotherapy group (-7.2 points) showing a significant improvement compared to the saline (-3.5 points; $p < 0.002$) and control groups (-3 points; $p < 0.001$). The WOMAC Total Score and pain VAS scores were also significantly improved in all treatment groups at 18 weeks, with a greater improvement in the prolotherapy group (WOMAC: -36 points and VAS: -6 points) compared to the saline group (WOMAC: -22.5 points, $p < 0.001$; VAS: -2.8 points, $p < 0.001$) and the control group (WOMAC: -9 points, $p = 0.002$; VAS: -2.4 points, $p < 0.001$). Rates of patients achieving a minimum clinically important difference of a 12-point change in the WOMAC score were not reported. There were no significant differences between the prolotherapy and saline groups on changes in Short Form 36 (SF-36) mental or physical component scores at 18 weeks. This study was limited by its small sample size and relatively short follow-up. The majority of the included population was composed of women (85.7 to 90.9% of groups) and adhered to the at home exercise regimen (85 to 87% of groups); both of these factors have been shown to increase benefit of prolotherapy limiting generalizability of the findings to all osteoarthritis patients.

Rabago (2013) reported a RCT of prolotherapy for knee osteoarthritis.^[10] This study was supported by the National Center for Complementary and Alternative Medicine (NCCAM). Ninety patients were randomized to at-home exercises ($n = 31$), or to 3-5 treatments with blinded injections of either dextrose prolotherapy ($n = 30$) in the treatment group or saline ($n = 29$) in the placebo group. Baseline characteristics were similar between groups except for significantly longer pre-treatment duration of knee pain in the placebo injection group, and significantly more prior physical therapy in the exercise group. All three groups showed improvements on the composite Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), with significantly greater improvement in the prolotherapy group (15.3 points) compared to saline and exercise groups (7.6, and 8.2 points, respectively). At 52 weeks, 50% of prolotherapy patients achieved the minimum clinically important difference (MCID) of a 12-point change in WOMAC, compared to 30% of saline-treated patients and 24% of exercise participants. Knee pain scores also improved more in the prolotherapy group. Limitations of the study methodology included the following: small per-group sample size; generalizability limited due to the numerous exclusion criteria; patients were relatively young; there was a lack of patients with very severe baseline WOMAC scores; and the lack of radiographs for some patients.

Rabago (2015) reported 2.5-year telephone follow-up from prolotherapy-treated patients in their randomized trial and from two uncontrolled open-label studies.^[11] The three prolotherapy groups were comparable, having undergone similar treatment courses and showing similar improvements in WOMAC score at 52 weeks (15.3, 12.4, 15.9 points, respectively). At a mean 2.5-year follow-up (range, 1.5-3.5 years), the 65 patients who agreed to participate in this follow-up study had a mean 20.9-point improvement in the WOMAC score. There is a risk of bias due to the open-label design and the relatively high proportion (10%) of prolotherapy-treated patients who declined to participate in the telephone interview.

Jahangiri (2014) reported a double-blind randomized trial that compared prolotherapy versus corticosteroid for the treatment of osteoarthritis in the first carpometacarpal joint.^[12] Sixty patients were randomized to three monthly prolotherapy injections or to two monthly saline injections plus a corticosteroid injection in the third month. The groups were comparable at baseline, with a VAS for pain on pressure of 6.7 in the prolotherapy group and 6.4 in the corticosteroid group. At the six month follow-up, pain had decreased more (by ≈ 2 cm VAS; final score, < 2) in the prolotherapy group compared with the corticosteroid-treated group ($p < 0.001$). Pain on movement and hand function had also improved to a greater extent in the prolotherapy group.

Reeves and Hassanein (2000) reported on two trials that used dextrose alone as a proliferant, thus eliminating the inflammatory response.^[13, 14] The first trial randomized 68 patients with 111 osteoarthritic knees to receive either three bimonthly injections of dextrose or placebo.^[13] The patients were evaluated with a visual analogue scale for pain and swelling, frequency of leg buckling, goniometrically measured flexion, and radiographic measures of joint narrowing. As the data were presented, it was clear that there was a significant improvement in both the placebo and treatment groups, but it is difficult to determine the comparative magnitude of improvement between the two groups. For example, for the various outcome measures of pain, it appears that there were probably no clinically significant incremental effects of prolotherapy compared to the placebo group. However, for other non-pain outcomes, e.g., swelling, buckling and flexion range, prolotherapy may be associated with a significant incremental improvement. The various outcome measures were combined as assessed using a Hotelling multivariate analysis. With this statistical measurement, prolotherapy demonstrated a statistically superior overall effect ($p = 0.015$) compared to the control group. It should be recognized that the statistical significance of this measure was most likely due to the improvements in the non-pain symptoms. It is not known whether the incremental improvement in the non-pain related outcomes of the prolotherapy group compared to the control group was clinically significant.

In a similarly designed study, the same investigators studied the effectiveness of prolotherapy as a treatment of osteoarthritic thumb and finger joints.^[14] A total of 27 patients with 150 osteoarthritic joints were randomized to receive three bimonthly injections of either dextrose or water. Patients were evaluated with both visual analogue scale (VAS) for pain and goniometric assessment of joint movement. Since patients had a variable number of joints injected (ranging from 1 to 22), the VAS score for every symptomatic joint for each patient was added together for a total and divided by the number of symptomatic joints to provide an average joint pain score for each patient. There were improvements in pain scores in both the placebo and treatment groups, but the incremental improvement in the treatment group compared to the placebo group did not reach statistical significance. In terms of flexion, the treatment group reported a statistically significant improvement ($p = 0.043$), while the placebo group reported a greater, statistically significant, decrease ($p = 0.011$). Therefore, the statistically significant difference in flexion between the two groups ($p = .003$) was primarily related to the decrease in the control group, with a smaller contribution related to the positive response in the treatment group. The clinical significance of an isolated finding of improved flexion without a corresponding significant improvement in pain is uncertain.

TENDINOPATHIES OF THE UPPER AND LOWER LIMBS

Systematic Reviews

Zhu (2022) conducted a systematic review and meta-analysis involving eight parallel or crossover RCTs (N=354) that evaluated the efficacy or effectiveness of dextrose prolotherapy on pain intensity and physical functioning in patients with lateral elbow tendinosis as compared to other active non-surgical treatments.^[15] Study sample sizes of the included RCTs ranged from 24 to 120 patients. The study periods ranged from 8 to 52 weeks with an injection frequency of one to four injections, weekly to four weeks apart; dextrose concentrations ranged from 12.5% to 50%. Comparison controls were classified into active (e.g., various injection solutions or therapies such as exercise, shock wave, laser, or manual therapy) or inactive (eg, no treatment, watchful waiting, bracing) categories. The primary outcome of interest was pain reduction, measured by VAS, numerical rating scale (NRS), or algometry. Secondary outcomes included handgrip strength, the Disabilities of the Arm, Shoulder, and Hand (DASH) score, and the Patient Rated Tennis Elbow Evaluation (PRTEE) score. Pooled results revealed dextrose prolotherapy to be significantly more effective than active controls at reducing pain intensity ($p=.04$) and improving DASH cumulative score ($p<.001$) at 12 weeks. However, dextrose prolotherapy had no significant effect on PRTEE cumulative score ($p=.70$) at 12 weeks or grip strength ($p=.90$) at 12 to 16 weeks. There were no significant related adverse events of dextrose prolotherapy. The overall quality of evidence ranged from very low to moderate with a high heterogeneity across the RCTs. Additionally, the number of studies included and the total participant sample size were small, the time frame available for pooling data was short (12 to 16 weeks), and quantitative syntheses included only a small number of studies in most comparisons.

Goh (2021) conducted a systematic review and network meta-analysis of the efficacy of prolotherapy in comparison to other treatments for patients with chronic soft tissue injuries (e.g., tendinopathies and enthesopathies) having a mean symptom duration lasting at least six weeks.^[16] The review included 91 articles (87 RCTs with 5859 subjects) involving upper limb (74%), lower limb (23%), and truncal/hip (3%) injuries. The "other treatments" within the network meta-analysis were primarily injections such as blood derivatives, corticosteroid, hyaluronic acid, and botulinum toxin. The primary outcome of interest was pain, evaluated mainly at a measurement time point six months post-intervention. If a six month time point was not available then measurements of pain at other times were evaluated. Results revealed that prolotherapy had no statistically significant benefits over other therapies with regard to pain relief at all assessed time points. However, prolotherapy was associated with better pain improvement over placebo at selected time points and injuries, primarily shoulder (<4 and >8 months) and elbow (4 to 8 months) injuries. The authors noted that more than 50% of included studies had a high overall risk of bias and some comparisons were connected by a small number of RCTs.

Chung (2020) published a systematic review and meta-analysis involving 10 RCTs (n=358) that analyzed the effects of dextrose prolotherapy on tendinopathy, fasciopathy, and ligament injuries.^[17] Included studies compared the effects of hypertonic dextrose prolotherapy to placebo, no prolotherapy, or corticosteroids and evaluated either pain or activity level at follow-up. Results revealed that there were no significant differences between dextrose prolotherapy and no treatment or placebo with regard to pain control for the majority of studies. Dextrose prolotherapy was effective in improving activity only at an immediate follow-up period of zero to one month (standardized mean difference [SMD], 0.98; 95% CI, 0.40 to 1.50) and was superior to steroid injections only in pain reduction at short-term follow-up (1 to 3 months; SMD, 0.70; 95% CI, 0.14 to 1.27). The authors concluded there was insufficient evidence to support the clinical benefits of dextrose prolotherapy in managing dense fibrous tissue injuries.

Three SR analyzed RCTs comparing various peritendinous injections with placebo or non-surgical interventions for tendinopathies.^[18-20] These reviews reported that, in trials of injections of corticosteroid, sclerosant, platelet-rich plasma, proteinase, glycosaminoglycan polysulfate, sodium hyaluronate, prolotherapy, and botulinum toxin compared with placebo injection or other therapies, only prolotherapy and sodium hyaluronate showed better results than placebo in the short and long term in overall improvement and pain reduction of lateral epicondylitis. These outcomes must be validated in larger, long-term, blinded RCTs.

Gross (2013) conducted a SR of RCTs and comparative cohort studies of various injection therapies for noninsertional Achilles tendinosis.^[21] Nine studies with 312 Achilles tendons at final follow-up met inclusion criteria. Injectates included platelet-rich plasma (n=54), autologous blood injection (n=40), sclerosing agents (n=72), protease inhibitors (n=26), hemodialysate (n=60), corticosteroids (n=52), and prolotherapy (n=20). The authors designated all studies as having a low quality of evidence with variable results, conflicting methodologies, and inconclusive evidence about indications for treatment and mechanisms of effects. The authors concluded that treatment recommendations for any injectable therapies for this condition would require additional data collected from RCTs.

Randomized Controlled Trials

Abd Karim (2023) published an RCT comparing platelet-rich plasma and prolotherapy in 64 patients with supraspinatus tendinopathy.^[22] The Shoulder and Pain Disability Index (SPADI) and Numerical Rating Scale (NRS) were the primary outcomes and were evaluated at baseline, three, and six months, which showed improvement in both groups. There were no other significant changes over time or between groups on any of the outcomes assessed in the study. This trial is limited by a small sample size and a lack of control group or standard of care comparator. Additional long-term follow-up data is needed to establish the durability of the treatment.

Two RCTs were published in 2020 evaluating the efficacy of dextrose prolotherapy in the treatment of lateral epicondylopathy/epicondylalgia.^[23] Both of these trials were conducted in Turkey in small patient populations. Akcay (2020) enrolled 60 subjects with chronic lateral epicondylopathy with randomization to dextrose 15% prolotherapy or normal saline injection. Results revealed that there was no significant difference between groups in VAS scores at rest or in motion, Disabilities of the Arm, Shoulder, and Hand (DASH) score, and handgrip strength at any time points in terms of improvement ($p > .05$). Dextrose prolotherapy was noted to outperform normal saline with regard to effect on the Patient Rated Tennis Elbow Evaluation (PRTEE). Additionally, a significant percentage of patients in both groups achieved an MCID for all outcome measurements at the end of 12 weeks with no significant difference among the groups in terms of MCID achievement ($p > .05$ for VAS at rest and motion, DASH, and PRTEE).

Apaydin (2020) compared the effects of dextrose prolotherapy to hyaluronic acid injection in 32 patients with lateral epicondylalgia.^[24] Overall, dextrose prolotherapy was favored over hyaluronic acid for improvements in pain with activity, at night, and at rest from baseline to 12 weeks. Dextrose prolotherapy was also associated with a significant improvement in quick-DASH scores. No between-group improvement in grip pain was observed. Results of both studies were limited by a short follow-up time, small sample size, and non-US-based, single center design.

A double-blind RCT reported by Bayat (2019) compared dextrose prolotherapy with corticosteroid injection for chronic lateral epicondylitis.^[25] Patients (n=28) received a single

injection during the treatment period. There was a significant improvement in VAS pain score at one and three month follow-up in both the prolotherapy group (mean difference: 1.9 and 4.4 points, respectively) and the corticosteroid group (mean difference: 1.5 and 1.9 points, respectively). No difference was observed between groups in VAS score at one month ($p=0.74$); however, prolotherapy resulted in significantly better scores at three months ($p=0.03$). At one month follow-up, no statistically significant difference was observed between the prolotherapy and corticosteroid groups in the Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) score (24.3 vs 34.8, respectively; $p=0.14$); however, Quick DASH score was significantly better with prolotherapy compared to corticosteroid at three months (score=14.7 vs 34.6, respectively; $p=0.01$). Results of this study are limited by a short follow-up, use of a single injection regimen, small sample size, and a notable non-significant difference in baseline symptom duration and QuickDASH score.

Bertrand (2016) reported on an RCT of prolotherapy in rotator cuff tendinopathy with supraspinatus pathology.^[26] A total of 73 participants were randomized to a blinded injection of dextrose prolotherapy ($n=27$), entheses saline injection ($n=20$), or superficial saline injection ($n=27$), all of which were given at months 0, 1, and 2, along with physical therapy. The primary outcome was achieving at least a 2.8 point improvement on the Numeric Rating Scale (NRS), which was obtained by phone by a blinded evaluator. Because the NRS rates pain in only whole numbers, pain levels are typically rated higher than with the VAS. For this reason, the improvement threshold was set as twice the minimal clinically important difference for VAS change in rotator cuff tendinopathy. After nine months, the primary outcome occurred in 59% of patients in the prolotherapy group, which was significantly higher than in the superficial saline group (27%; $p=0.017$) and similar to the entheses saline group (37%; $p=0.088$). Patient satisfaction at 9 months, assessed using a 10-point satisfaction scale (0=not satisfied, 10=completely satisfied), revealed highest satisfaction in the prolotherapy group (6.7 points), followed by entheses saline (4.7 points; $p=0.079$ compared to prolotherapy) and superficial saline (3.9 points; $p=0.003$ compared to prolotherapy). Scores from the Ultrasound Shoulder Pathology Rating Scale did not differ significantly between groups ($p=0.734$). Important limitations of this study are the single-center design, which may limit generalizability to all patients. Additionally, the entheses saline injection group was not sufficiently powered to find a difference from the prolotherapy group. Finally, the use of the NRS as an alternative to the VAS may have biased the measurement of pain improvement.

One double-blind trial compared the efficacy of prolotherapy with placebo (saline injections) in 20 patients with elbow pain for at least six months and failure of conservative therapy (rest, physical therapy, nonsteroidal anti-inflammatory drugs, and two corticosteroid injections).^[27] Injections were performed three times over eight weeks. At 16 weeks follow-up there was a significant improvement in pain (from 5.1 to 0.5 on a Likert scale) in the prolotherapy group compared with the placebo group (4.5 to 3.5). Isometric strength also improved (13 to 31lb vs. 10 to 11 lb), but there was no difference in grip strength between the two treatments. The authors indicated that this is the first randomized trial of prolotherapy for tendinopathy; additional research with a larger study population is needed.

Carayannopoulos (2011) randomized 24 patients with lateral epicondylitis of at least three months duration to receive either prolotherapy or corticosteroid injection.^[28] This was a double-blind study. All subjects received an injection at baseline and a second injection one month later. Both groups reported significant improvement, but there was no significant difference in pain and disability measures between the two groups.

OTHER MUSCULOSKELETAL PAIN

Dextrose prolotherapy has been investigated in temporomandibular joint dysfunction. In 2011, a preliminary randomized, double-blind, placebo-controlled clinical trial was conducted on patients with temporomandibular joint hypermobility.^[29] Since then, Sit (2021) has performed a systematic review and meta-analysis of five RCTs that compare the efficacy of hypertonic dextrose prolotherapy injections to placebo in patients with temporomandibular joint dysfunction.^[30]

Current published literature for prolotherapy for other musculoskeletal disorders is limited to preliminary feasibility studies of conditions such as Achilles tendinopathy^[18], anterior cruciate ligament laxity^[31], osteitis pubis^[32], rotator cuff tendinopathy^[33], plantar fasciitis^[34], and bursitis.^[35] These studies do not permit conclusions on the efficacy or safety of prolotherapy due to lack of randomization and placebo-control groups, small study populations, and short-term study duration.

PRACTICE GUIDELINE SUMMARY

AMERICAN ASSOCIATION OF ORTHOPEDIC MEDICINE

As of September 2020, the American Association of Orthopedic Medicine (AAOM) currently has a recommendation posted online for the use of prolotherapy for back pain, with an unknown original publication date.^[36] The AAOM has indicated that "...prolotherapy should be considered a valid treatment option in a selected group of chronic low back pain patients."

AMERICAN COLLEGE OF RHEUMATOLOGY/ARTHRITIS FOUNDATION

The 2019 American College of Rheumatology/Arthritis Foundation guideline for osteoarthritis of the hand, hip, and knee conditionally recommends against the use of prolotherapy in patients with knee and/or hip osteoarthritis, given limited number of trials involving small sample sizes showing limited effect.^[37] The guideline does not make any recommendation regarding hand osteoarthritis, given lack of trials.

SUMMARY

There is not enough research to show that prolotherapy improves health outcomes for people for any indication. Clinical practice guidelines are inconclusive on the use of prolotherapy for the treatment of musculoskeletal pain. Therefore, prolotherapy is considered investigational for all indications, including but not limited to musculoskeletal pain.

REFERENCES

1. Dagenais S, Yelland MJ, Del Mar C, et al. Prolotherapy injections for chronic low-back pain. *Cochrane Database Syst Rev*. 2007(2):CD004059. PMID: 17443537
2. Dagenais S, Mayer J, Haldeman S, et al. Evidence-informed management of chronic low back pain with prolotherapy. *Spine J*. 2008;8(1):203-12. PMID: 18164468
3. Chou R, Atlas SJ, Stanos SP, et al. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. *Spine (Phila Pa 1976)*. 2009;34(10):1078-93. PMID: 19363456

4. Kim WM, Lee HG, Jeong CW, et al. A randomized controlled trial of intra-articular prolotherapy versus steroid injection for sacroiliac joint pain. *J Altern Complement Med*. 2010;16(12):1285-90. PMID: 21138388
5. Cortez VS, Moraes WA, Taba JV, et al. Comparing dextrose prolotherapy with other substances in knee osteoarthritis pain relief: A systematic review. *Clinics (Sao Paulo)*. 2022;77:100037. PMID: 35594623
6. Arias-Vázquez PI, Tovilla-Zárate CA, Castillo-Avila RG, et al. Hypertonic Dextrose Prolotherapy, an Alternative to Intra-Articular Injections With Hyaluronic Acid in the Treatment of Knee Osteoarthritis: Systematic Review and Meta-analysis. *Am J Phys Med Rehabil*. 2022;101(9):816-25. PMID: 34740224
7. Wee TC, Neo EJR, Tan YL. Dextrose prolotherapy in knee osteoarthritis: A systematic review and meta-analysis. *J Clin Orthop Trauma*. 2021;19:108-17. PMID: 34046305
8. Waluyo Y, Artika SR, Insani Nanda W, et al. Efficacy of Prolotherapy for Osteoarthritis: A Systematic Review. *J Rehabil Med*. 2023;55:jrm00372. PMID: 36847731
9. Sert AT, Sen EI, Esmailzadeh S, et al. The Effects of Dextrose Prolotherapy in Symptomatic Knee Osteoarthritis: A Randomized Controlled Study. *J Altern Complement Med*. 2020;26(5):409-17. PMID: 32223554
10. Rabago D, Patterson JJ, Mundt M, et al. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. *Ann Fam Med*. 2013;11:229-37. PMID: 23690322
11. Rabago D, Mundt M, Zgierska A, et al. Hypertonic dextrose injection (prolotherapy) for knee osteoarthritis: Long term outcomes. *Complementary therapies in medicine*. 2015;23(3):388-95. PMID: 26051574
12. Jahangiri A, Moghaddam FR, Najafi S. Hypertonic dextrose versus corticosteroid local injection for the treatment of osteoarthritis in the first carpometacarpal joint: a double-blind randomized clinical trial. *Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association*. 2014;19(5):737-43. PMID: 25158896
13. Reeves KD, Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. *Altern Ther Health Med*. 2000;6(2):68-74, 77-80. PMID: 10710805
14. Reeves KD, Hassanein K. Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumb and finger (DIP, PIP, and trapeziometacarpal) joints: evidence of clinical efficacy. *J Altern Complement Med*. 2000;6(4):311-20. PMID: 10976977
15. Zhu M, Rabago D, Chung VC, et al. Effects of Hypertonic Dextrose Injection (Prolotherapy) in Lateral Elbow Tendinosis: A Systematic Review and Meta-analysis. *Arch Phys Med Rehabil*. 2022;103(11):2209-18. PMID: 35240122
16. Goh SL, Jaafar Z, Gan YN, et al. Efficacy of prolotherapy in comparison to other therapies for chronic soft tissue injuries: A systematic review and network meta-analysis. *PLoS One*. 2021;16(5):e0252204. PMID: 34038486
17. Chung MW, Hsu CY, Chung WK, et al. Effects of dextrose prolotherapy on tendinopathy, fasciopathy, and ligament injuries, fact or myth?: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2020;99(46):e23201. PMID: 33181700
18. Distel LM, Best TM. Prolotherapy: a clinical review of its role in treating chronic musculoskeletal pain. *PM R*. 2011;3(6 Suppl 1):S78-81. PMID: 21703585
19. Hart L. Corticosteroid and other injections in the management of tendinopathies: a review. *Clin J Sport Med*. 2011;21(6):540-1. PMID: 22064721
20. Krogh TP, Bartels EM, Ellingsen T, et al. Comparative effectiveness of injection therapies in lateral epicondylitis: a systematic review and network meta-analysis of randomized controlled trials. *Am J Sports Med*. 2013;41:1435-46. PMID: 22972856

21. Gross CE, Hsu AR, Chahal J, et al. Injectable treatments for noninsertional achilles tendinosis: a systematic review. *Foot Ankle Int.* 2013;34:619-28. PMID: 23637232
22. Abd Karim S, Hamid MS, Choong A, et al. Effects of platelet-rich plasma and prolotherapy on supraspinatus tendinopathy: a double blind randomized clinical trial. *J Sports Med Phys Fitness.* 2023;63(5):674-84. PMID: 37132278
23. Akcay S, Gurel Kandemir N, Kaya T, et al. Dextrose Prolotherapy Versus Normal Saline Injection for the Treatment of Lateral Epicondylopathy: A Randomized Controlled Trial. *J Altern Complement Med.* 2020;26(12):1159-68. PMID: 32990454
24. Apaydin H, Bazancir Z, Altay Z. Injection Therapy in Patients with Lateral Epicondylalgia: Hyaluronic Acid or Dextrose Prolotherapy? A Single-Blind, Randomized Clinical Trial. *J Altern Complement Med.* 2020;26(12):1169-75. PMID: 32931308
25. Bayat M, Raeissadat SA, Mortazavian Babaki M, et al. Is Dextrose Prolotherapy Superior To Corticosteroid Injection In Patients With Chronic Lateral Epicondylitis?: A Randomized Clinical Trial. *Orthop Res Rev.* 2019;11:167-75. PMID: 31819675
26. Bertrand H, Reeves KD, Bennett CJ, et al. Dextrose Prolotherapy Versus Control Injections in Painful Rotator Cuff Tendinopathy. *Arch Phys Med Rehabil.* 2016;97(1):17-25. PMID: 26301385
27. Scarpone M, Rabago DP, Zgierska A, et al. The efficacy of prolotherapy for lateral epicondylitis: a pilot study. *Clin J Sport Med.* 2008;18(3):248-54. PMID: 18469566
28. Carayannopoulos A, Borg-Stein J, Sokolof J, et al. Prolotherapy versus corticosteroid injections for the treatment of lateral epicondylitis: a randomized controlled trial. *PM R.* 2011;3(8):706-15. PMID: 21871414
29. Refai H, Altahhan O, Elsharkawy R. The efficacy of dextrose prolotherapy for temporomandibular joint hypermobility: a preliminary prospective, randomized, double-blind, placebo-controlled clinical trial. *J Oral Maxillofac Surg.* 2011;69(12):2962-70. PMID: 21757278
30. Sit RW, Reeves KD, Zhong CC, et al. Efficacy of hypertonic dextrose injection (prolotherapy) in temporomandibular joint dysfunction: a systematic review and meta-analysis. *Sci Rep.* 2021;11(1):14638. PMID: 34282199
31. Reeves KD, Hassanein KM. Long-term effects of dextrose prolotherapy for anterior cruciate ligament laxity. *Altern Ther Health Med.* 2003;9(3):58-62. PMID: 12776476
32. Choi H, McCartney M, Best TM. Treatment of osteitis pubis and osteomyelitis of the pubic symphysis in athletes: a systematic review. *Br J Sports Med.* 2011;45(1):57-64. PMID: 18812419
33. Kazempour Mofrad M, Rezasoltani Z, Dadarkhah A, et al. Periarticular Neurofascial Dextrose Prolotherapy Versus Physiotherapy for the Treatment of Chronic Rotator Cuff Tendinopathy: Randomized Clinical Trial. *J Clin Rheumatol.* 2021;27(4):136-42. PMID: 32975923
34. Mansiz-Kaplan B, Nacir B, Pervane-Vural S, et al. Effect of Dextrose Prolotherapy on Pain Intensity, Disability, and Plantar Fascia Thickness in Unilateral Plantar Fasciitis: A Randomized, Controlled, Double-Blind Study. *Am J Phys Med Rehabil.* 2020;99(4):318-24. PMID: 31738283
35. Chang YJ, Chang FH, Hou PH, et al. Effects of Hyperosmolar Dextrose Injection in Patients With Rotator Cuff Disease and Bursitis: A Randomized Controlled Trial. *Arch Phys Med Rehabil.* 2021;102(2):245-50. PMID: 32926850
36. (AAOM) AAOM. Prolotherapy for Back Pain Treatment. [cited 3/19/2024]. 'Available from:' <https://www.aaomed.org/prolotherapy-back-pain>.

37. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Rheumatol.* 2020;72(2):220-33. PMID: 31908163

CODES

Codes	Number	Description
CPT	20999	Unlisted procedure, musculoskeletal system, general
HCPCS	M0076	Prolotherapy

Date of Origin: November 1997